论文信息 - SARS-CoV-2 binding and neutralizing antibody levels after Ad26.COV2.S vaccination predict durable protection in rhesus macaques - 字舞流文

SARS-CoV-2 binding and neutralizing antibody levels after Ad26.COV2.S vaccination predict durable protection in rhesus macaques

H. Schuitemaker | N. Guimerà | J. Pérez-Ruixo | F. Wegmann | S. Tete | R. Roozendaal | L. Dekking | W. Koudstaal | L. Solforosi | D. Barouch | Jingyou Yu | A. Chandrashekar | N. Mercado | S. R. Rosendahl Huber | A. Dari | Sietske K. Rosendahl Huber | J. Sadoff | D. Stieh | M. Boulton | J. Hendriks | Joan E. M. van der Lubbe | D. Czapska-Casey | R. Zahn | J. Serroyen | M. le Gars | Sarah Janssen | R. Straetemans | Muriel Boulton | Mathieu le Gars | Liesbeth Dekking | Jan Serroyen | Sarah M. Tete

[1] J. Mascola,et al. Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates , 2021, Science.

[2] H. Schuitemaker,et al. Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques , 2021, Cell.

[3] M. Davenport,et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection , 2021, Nature Medicine.

[4] H. Schuitemaker,et al. Immunogenicity and efficacy of one and two doses of Ad26.COV2.S COVID vaccine in adult and aged NHP , 2021, Journal of Experimental Medicine.

[5] H. Fennema,et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 , 2021, The New England journal of medicine.

[6] H. Schuitemaker,et al. Low-Dose Ad26.COV2.S Protection Against SARS-CoV-2 Challenge in Rhesus Macaques , 2021, bioRxiv.

[7] M. Nussenzweig,et al. Evolution of antibody immunity to SARS-CoV-2 , 2021, Nature.

[8] D. Lauffenburger,et al. Correlates of Protection Against SARS-CoV-2 in Rhesus Macaques , 2020, Nature.

[9] H. Schuitemaker,et al. Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate , 2020, NPJ vaccines.

[10] M. Nussenzweig,et al. Evolution of Antibody Immunity to SARS-CoV-2 , 2020, bioRxiv.

[11] A. Goyal,et al. Potency and timing of antiviral therapy as determinants of duration of SARS-CoV-2 shedding and intensity of inflammatory response , 2020, Science Advances.

[12] D. Lauffenburger,et al. Single-Shot Ad26 Vaccine Protects Against SARS-CoV-2 in Rhesus Macaques , 2020, Nature.

[13] R. Baric,et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques , 2020, Science.

[14] P. Sorger,et al. SARS-CoV-2 infection protects against rechallenge in rhesus macaques , 2020, Science.

[15] A. Goyal,et al. Potency and timing of antiviral therapy as determinants of duration of SARS CoV-2 shedding and intensity of inflammatory response , 2020, medRxiv.

[16] P. Vollmar,et al. Virological assessment of hospitalized patients with COVID-2019 , 2020, Nature.

[17] D. Bates,et al. Fitting Linear Mixed-Effects Models Using lme4 , 2014, 1406.5823.

[18] M. Fay,et al. Anthrax Vaccine–Induced Antibodies Provide Cross-Species Prediction of Survival to Aerosol Challenge , 2012, Science Translational Medicine.

[19] P. Gilbert,et al. Nomenclature for immune correlates of protection after vaccination. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20] Lynn McFadyen,et al. Basic PK/PD principles of drug effects in circular/proliferative systems for disease modelling , 2010, Journal of Pharmacokinetics and Pharmacodynamics.

[21] J. Wittes,et al. Correlates, surrogates, and vaccines. , 2007, The Journal of infectious diseases.

[22] Gary J. Nabel,et al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice , 2004, Nature.

[23] D. Firth. Bias reduction of maximum likelihood estimates , 1993 .